EVEROLIMUS-ELUTING VERSUS SIROLIMUS-ELUTING STENTS: AN UPDATED META-ANALYSIS OF RANDOMIZED TRIALS  by deWaha, Antoinette et al.
Chronic CAD/Stable Ischemic Heart Disease
E1507
JACC March 27, 2012
Volume 59, Issue 13
EVEROLIMUS-ELUTING VERSUS SIROLIMUS-ELUTING STENTS: AN UPDATED META-ANALYSIS OF 
RANDOMIZED TRIALS
ACC Moderated Poster Contributions
McCormick Place South, Hall A
Monday, March 26, 2012, 11:00 a.m.-Noon
Session Title: DES vs. BMS: Do We Have the Answer?
Abstract Category: 2. Chronic CAD/Stable Ischemic Heart Disease: Clinical
Presentation Number: 1204-313
Authors: Antoinette de Waha, Salvatore Cassese, Robert Byrne, Tomohisa Tada, lamin king, Adnan Kastrati, Albert Schoemig, Deutsches Herzzentrum 
and 1. Med. Klinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany
Background: Everolimus-eluting stents (EES) are among the most commonly used second-generation drug-eluting stents in clinical practice and 
have clearly-proven superiority over paclitaxel-eluting stents. Nevertheless, the relative merits of EES against the previous gold-standard sirolimus-
eluting stent (SES) have been less extensively assessed. We aimed to compare the clinical outcomes of EES with SES in patients undergoing 
percutaneous coronary intervention.
Methods and Results: We identified 8 eligible randomized trials comparing EES with SES including 11,167 patients. The primary endpoint was 
the incidence of major adverse cardiac events (MACE). Secondary endpoints were target lesion revascularization (TLR) and the composite of definite 
and probable stent thrombosis. No heterogeneity across the trials was observed regarding the endpoints. There was no difference in risk of MACE 
(HR, 0.91 [0.79 to 1.04]; p=0.15), TLR (HR, 0.86 [0.72 to 1.04]; p=0.12) and the composite of definite and probable stent thrombosis (HR, 0.84 
[0.54 to 1.29], p=0.42). The risk of definite stent thrombosis was significantly lower in patients receiving EES (HR, 0.49 [0.27 to 0.91], p=0.02).
Conclusions: Using the largest available dataset of patients treated in randomized trials the present meta-analysis demonstrated that the use of 
EES versus SES was associated with comparable incidence of overall clinical events. However, EES may be associated with a lower risk of definite 
stent thrombosis.
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